Background/Objectives: Erectile dysfunction (ED) is a prevalent and multifactorial condition influenced by psychological and sleep-related factors. This study aimed to evaluate the independent and combined associations of insomnia and benzodiazepine use with the risk of ED. Methods: An analytical cross-sectional study was conducted in adult men with and without ED. Logistic regression was used to estimate crude and adjusted odds ratios (ORs). Effect modification was assessed through stratified analyses. Additionally, an in silico analysis of 17 active compounds was performed using SwissADME and Molinspiration to explore physicochemical properties. Results: Insomnia (adjusted OR 2.05; 95% CI 1.13–3.74; p = 0.019) and benzodiazepine use (adjusted OR 2.14; 95% CI 1.10–4.15; p = 0.025) were each independently associated with ED. In contrast, antidepressant use was not significantly associated with ED in the sample analyzed. Participants with both insomnia and benzodiazepine use had a markedly higher risk (adjusted OR 3.96; 95% CI 1.51–10.40; p = 0.005). The joint association of insomnia and benzodiazepine use was consistent with the combined effect expected from their individual associations. The in silico analysis showed an overlapping profile, suggesting benzodiazepine properties may underline their link to ED, supporting the results of the cross-sectional study. Conclusions: Both insomnia and benzodiazepine use independently increased the odds of ED. Their co-occurrence was linked to a substantially higher likelihood of ED, highlighting the clinical importance of assessing both conditions concurrently in patients with sexual dysfunction.
Background/Objectives: Erectile dysfunction (ED) is a prevalent and multifactorial condition influenced by psychological and sleep-related factors. This study aimed to evaluate the independent and combined contributions of insomnia and antidepressant use to the risk of ED. Methods: A case-control study was conducted including adult men with and without ED. Logistic regression was used to estimate crude and adjusted odds ratios (ORs). A stepwise multivariable model (entry p < 0.5, exit p < 0.1) identified significant predictors. Effect modification was explored through stratified analyses and additive interaction indices: relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S). Results: Insomnia (adjusted OR 1.98; 95% CI 1.09–3.60; p = 0.026) and antidepressant use (adjusted OR 2.04; 95% CI 1.12–3.72; p = 0.021) were each independently associated with ED. Participants with both exposures had a markedly higher risk (adjusted OR 3.94; 95% CI 1.67–9.26; p = 0.002). However, interaction indices (RERI ≈ 0.03; S ≈ 1.01) suggested no statistically significant synergistic interaction. The combined effect approximated the sum of individual effects, indicating an additive rather than synergistic relationship. Conclusions: Both insomnia and antidepressant use independently increased the odds of ED. Although no significant statistical interaction was found, their co-occurrence was associated with a substantially higher risk, underscoring the clinical importance of evaluating and addressing both factors in the management of ED.